June 11 (Reuters) - Novavax Inc said on Friday its COVID-19 vaccine candidate showed immune response and protection against the SARS-CoV-2 Beta variant, which was originally identified in South Africa, in three animal and human studies. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
Pre-market 08:03:31 am | |||
16 USD | -11.92% | 15.62 | -2.44% |
Jun. 07 | COVID shots should target JN.1 variants in 2024-25 campaign, US FDA says | RE |
Jun. 06 | S&P 500, Nasdaq dip on the eve of US payrolls data | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+233.44% | 2.25B | |
+49.41% | 56.95B | |
+40.40% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : says COVID-19 vaccine candidate shows immune response against Beta variant